Your browser doesn't support javascript.
loading
Self-Report versus Clinician Examination in Early Parkinson's Disease.
Zolfaghari, Sheida; Thomann, Alessandra E; Lewandowski, Natalia; Trundell, Dylan; Lipsmeier, Florian; Pagano, Gennaro; Taylor, Kirsten I; Postuma, Ronald B.
  • Zolfaghari S; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada.
  • Thomann AE; Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • Lewandowski N; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Basel, Switzerland.
  • Trundell D; Faculty of Science, McGill University, Montreal, Quebec, Canada.
  • Lipsmeier F; Roche Products Limited, Welwyn Garden City, United Kingdom.
  • Pagano G; Roche Pharma Research and Early Development, pRED Informatics, Roche Innovation Center, Basel, Switzerland.
  • Taylor KI; Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area, Basel, Switzerland.
  • Postuma RB; King's College London, London, United Kingdom.
Mov Disord ; 37(3): 585-597, 2022 03.
Article en En | MEDLINE | ID: mdl-34897818
ABSTRACT

BACKGROUND:

Evaluating the discrepancies between patient-reported measures and clinician examination has implications for formulating individual treatment regimens.

OBJECTIVE:

This study investigated the association between health outcomes and level of self-reported motor-related function impairment relative to clinician-examined motor signs.

METHODS:

Recently diagnosed PD patients were evaluated using the Parkinson's Progression Marker Initiative (PPMI, N = 420) and the PASADENA phase II clinical trial (N = 316). We calculated the average normalized difference between each participant's part II and III MDS-UPDRS (Movement Disorder Society Unified Parkinson's Disease Rating Scale) scores. Individuals with score differences <25th or >75th percentiles were labeled as low- and high-self-reporters, respectively (those between ranges were labeled intermediate-self-reporters). We compared a wide range of clinical/biomarker readouts among these three groups, using Kruskal-Wallis nonparametric and Pearson's χ2 tests. Spearman's correlations were tested for associations between MDS-UPDRS subscales.

RESULTS:

In both cohorts, high-self-reporters reported the largest impairment/symptom experience for most motor and nonmotor patient-reported variables. By contrast, these high-self-reporters were similar to or less impaired on clinician-examined and biomarker measures. Patient-reported nonmotor symptoms on MDS-UPDRS part IB showed the strongest positive correlation with self-reported motor-related impairment (PPMI rs  = 0.54, PASADENA rs  = 0.52). This correlation was numerically stronger than the part II and clinician-examined MDS-UPDRS part III correlation (PPMI rs  = 0.38, PASADENA rs  = 0.28).

CONCLUSION:

Self-reported motor-related impairments reflect not only motor signs/symptoms but also other self-reported nonmotor measures. This may indicate (1) a direct impact of nonmotor symptoms on motor-related functioning and/or (2) the existence of general response tendencies in how patients self-rate symptoms. Our findings suggest further investigation into the suitability of MDS-UPDRS II to assess motor-related impairments. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Año: 2022 Tipo del documento: Article